Finance

Lists
Q2 2026 earnings • released • EPS beat +30.28% • Revenue beat +3.28%
See results
AMRX:NASDAQ
Amneal Pharmaceuticals Inc
$18.32
-0.97%
(-0.18) 1D
Jul 31, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for AMRX...
Open
$18.17
High
$18.43
Low
$17.92
Mkt. cap
5.85B
Avg. vol.
2.14M
Volume
0.00
P/E ratio
49.12
52-wk high
$19.26
52-wk low
$7.66
EPS
$0.37
Beta
1.26
Shares outstanding
319.33M
No. of employees
9K
Open
$18.17
High
$18.43
Low
$17.92
Mkt. cap
5.85B
Avg. vol.
2.14M
Volume
0.00
P/E ratio
49.12
52-wk high
$19.26
52-wk low
$7.66
EPS
$0.37
Beta
1.26
Shares outstanding
319.33M
No. of employees
9K
News stories
From sources across the web
Profile
Amneal Pharmaceuticals, Inc. is an American publicly traded pharmaceutical company that develops, manufactures and distributes generics and specialty pharmaceutical products. The company is headquartered in Bridgewater, New Jersey, and is one of the largest manufacturers of generic drugs in the United States. Wikipedia
About Amneal Pharmaceuticals Inc
CEOChintu Patel | Chirag Patel
Employees8.7K
Founded2002
HeadquartersBridgewater, New Jersey, United States
SectorPharmaceutical industry
Websiteamneal.com
Analyst ratings
Based on 4 analysts giving stock ratings to AMRX in the past 3 months
Strong buy
Buy
4
Hold
0
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for AMRX in the last 3 months.
Highest
Current $18.32
$23.00 (+25.55%)
Average
$19.25 (+5.08%)
Lowest
$16.00 (-12.66%)
Analyst
Recommendation
Action
Price target
Projected
Date
Salveen Richter
Goldman Sachs
Buy
Reiterated
$21.00
+14.6%
07/31/2026
David Amsellem
Piper Sandler
Buy
Reiterated
$17.00
-7.2%
07/20/2026
Ashwani Verma
UBS
Buy
Maintained
$23.00
+25.5%
07/15/2026
Glen Santangelo
Barclays
Buy
Maintained
$16.00
-12.7%
06/11/2026
Matthew Dellatorre
Goldman Sachs
Buy
Reiterated
$17.00
-7.2%
05/27/2026
Les Sulewski
Truist Financial
Buy
Maintained
-
-
04/23/2026
Chris Schott
J.P. Morgan
Buy
Maintained
$18.00
-1.7%
03/02/2026
Last report
Jul 30, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
$0.30 / $0.23
+30.28%beat
Revenue / Est. (USD)
796.20M / 770.91M
+3.28%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
784.51M
814.32M
722.52M
796.20M
Cost of goods sold
490.19M
518.54M
403.95M
463.78M
Cost of revenue
490.19M
518.54M
403.95M
463.78M
Research and development expenses
63.35M
34.79M
38.38M
39.02M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
137.82M
146.48M
138.86M
148.22M
Operating expense
201.05M
181.28M
177.18M
185.94M
Total operating expenses
691.24M
699.82M
581.13M
649.72M
Operating income
93.27M
114.50M
141.39M
146.48M
Other non operating income
22.04M
876.00K
3.08M
-1.79M
EBT including unusual items
-5.22M
55.24M
80.18M
70.99M
EBT excluding unusual items
49.07M
57.70M
83.31M
87.70M
Income tax expense
-23.36M
5.66M
2.18M
1.38M
Effective tax rate
447.16%
10.25%
2.71%
1.94%
Other operating expenses
-117.00K
-1.00K
-64.00K
-1.30M
Net income
2.37M
35.08M
62.26M
57.66M
Net profit margin
0.30%
4.31%
8.62%
7.24%
Earnings per share
0.17
0.21
0.27
0.30
Interest and investment income
-
-
-
-
Interest expense
-62.81M
-56.24M
-53.36M
-55.04M
Net interest expenses
-62.81M
-56.24M
-53.36M
-55.04M
Depreciation and amortization charges
-
-
-
-
EBITDA
147.34M
163.73M
184.58M
194.28M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps